Overview of Niflumic Acid

Property	Description
Active ingredient	Niflumic Acid
Form	Solid oral preparations (capsules), Topical preparations (gel)
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common purpose	Relief from general pain, inflammation, and fever
Origin	Synthetic organic compound

Type and Classification of Niflumic Acid

Niflumic Acid is a pharmaceutical agent classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), a major therapeutic class utilized for its ability to reduce inflammation, alleviate pain, and lower body temperature. This synthetic organic compound belongs chemically to the fenamate subgroup of NSAIDs, distinguishing it from substances like aspirin. Pharmacological data supports Niflumic Acid's established classification within this category, and the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) system identifies it with codes such as M01AX02 for systemic administration, confirming its role as an anti-inflammatory and antirheumatic agent.

Composition and Available Forms

The medication generally consists of Niflumic Acid as the single-active ingredient, identified by its International Nonproprietary Name (INN). Niflumic Acid is prepared in multiple dosage form(s), including solid oral preparations (such as capsules) for systemic absorption and topical preparations (such as gels) for local application to a targeted area. This formulation choice, particularly the development of its topical preparation, is a key differentiating factor, making it suitable for managing localized musculoskeletal discomfort. The European Medicines Agency (EMA) lists various products containing Niflumic Acid in both oral and cutaneous preparations.

How Does Niflumic Acid Work at a High Level?

Niflumic Acid fundamentally exerts its effects by inhibiting the body's inflammatory signaling processes. The drug's primary action involves blocking the cyclooxygenase (COX) enzymes, which directly halts the production of prostaglandins—the chemical mediators essential for the experience of pain, swelling, and fever. Niflumic Acid acts as a COX inhibitor to reduce inflammation. Beyond this core NSAID action, the substance is also known to influence certain cellular signaling channels, such as chloride channels, contributing to its overall ability to modulate tissue excitability and reduce painful sensations.

Regulatory References

What side effects are possible with Niflumic Acid?

The safety profile of Niflumic Acid, an NSAID, is structured by government regulatory documents based on system-organ class and frequency of occurrence. These classifications provide a formal description of the medicine’s risk characteristics.

Documented Adverse Reactions

The most commonly listed adverse effects (classified as Common in regulatory documents) primarily involve the Gastrointestinal System, including abdominal pain, nausea, vomiting, and diarrhea. Effects classified as Uncommon include those affecting the Nervous System, such as headache and vertigo, and hypersensitivity reactions (e.g., skin rash).

Serious Safety Considerations

Official labeling highlights the potential for Serious Adverse Reactions. These include risks of gastrointestinal hemorrhage, ulceration, and perforation, as well as severe, rare dermatological events like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The risk of serious cardiovascular thrombotic events is also a documented class-wide safety concern. Serious reactions such as acute renal failure and specific hematological disorders (e.g., agranulocytosis) are also officially noted.

Population and Exposure Constraints

Safety notes specify that older adults are at an increased risk of serious adverse reactions, particularly gastrointestinal complications. The medicine is formally contraindicated in individuals with active or recurrent peptic ulcer/hemorrhage and in cases of severe renal or hepatic impairment. Regulatory documents specify that gastrointestinal side effects are often more frequent at the start of treatment, while the risk of severe events may be associated with longer duration of use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation on Niflumic Acid overdose outlines the expected clinical manifestations and mandated emergency responses.

Feature	Official Regulatory Statement
Documented overdose presentations	Symptoms are usually benign, frequently involving signs of digestive irritation, drowsiness, and headaches.
Physiological systems affected (as stated in label)	Gastrointestinal system, renal system (e.g., acute glomerulonephritis), and central nervous system.
Dose-related or exposure-related factors	Severe renal outcomes (acute glomerulonephritis) were documented in a case involving a massive 7.5 g ingestion.
Emergency-response statements (as written in official documents)	Mandates immediate transfer to a hospital setting. Management includes rapid evacuation of the ingested product by gastric lavage.

Overdose classifications (high-level)

Feature	Official Regulatory Statement
Severity classification (as defined in official documents)	Clinical symptomatology is usually benign, although severe complications are documented.
Overdose-context constraints (as defined in official documents)	Treatment is symptomatic and supportive; no specific antidote is known.

Resulting overdose structure

Official overdose statements:

Symptoms are generally documented as usually benign, with the most frequent presentation being signs of digestive irritation.
A severe outcome, acute glomerulonephritis, has been documented following massive ingestion, though it was noted to be reversible without sequelae.
Immediate transfer to a hospital setting is officially required following suspected overdose.
No specific antidote is known for Niflumic Acid.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the overdose profile by balancing the typically benign presentation of digestive and CNS symptoms against the documented risk of severe renal complications. Due to the potential for serious outcomes, regulators mandate immediate transfer to a hospital setting for management, including necessary procedural steps like gastric lavage, as the treatment remains symptomatic and supportive.

Therapeutic Uses of Niflumic Acid

Main Uses and Therapeutic Applications

Niflumic acid is a non-steroidal anti-inflammatory drug (NSAID) primarily utilized for its analgesic and anti-inflammatory properties. It is indicated for the treatment of various acute and chronic conditions characterized by pain and inflammation.

Inflammatory Joint Diseases

The primary use of niflumic acid involves the management of inflammatory musculoskeletal disorders. It is frequently employed to alleviate symptoms associated with:

Rheumatoid Arthritis: A chronic inflammatory disorder affecting the joints.
Osteoarthritis: Degenerative joint disease, particularly during painful flare-ups.
Ankylosing Spondylitis: A type of arthritis that affects the spine and large joints.

Acute Musculoskeletal Conditions

Niflumic acid is also used for the short-term treatment of acute painful episodes related to the soft tissues and skeletal system. This includes:

Tendinitis and Tenosynovitis: Inflammation of the tendons or the sheath surrounding them.
Bursitis: Inflammation of the fluid-filled sacs that cushion the joints.
Sprains and Strains: Relief of pain following minor physical injuries or mechanical trauma.

Ear, Nose, and Throat (ENT) and Dental Applications

Due to its ability to reduce localized swelling and pain, niflumic acid may be used as an adjunctive treatment for inflammatory conditions in the ENT and dental fields, such as:

Pharyngitis and Tonsillitis: Reducing the discomfort associated with severe throat inflammation.
Post-operative Pain: Management of pain following dental procedures or minor surgeries.

Therapeutic Benefits

The benefit of niflumic acid lies in its mechanism of inhibiting prostaglandin synthesis, which are the chemicals in the body responsible for signaling pain and promoting inflammation. By targeting these mediators, the medication provides:

Reduction of Edema: Helping to decrease swelling in affected joints or tissues.
Improved Mobility: By reducing pain and stiffness, it may help restore a greater range of motion in patients with chronic joint conditions.
Analgesic Effect: Providing relief from mild to moderate pain levels.

Regulatory References

Australian Therapeutic Goods Administration (TGA) on NSAID indications

Eligibility and Restrictions for Use

Who Can and Cannot Use Niflumic Acid

The eligibility profile for Niflumic Acid is governed by regulatory constraints specific to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Contraindications (Must Not Use)

Niflumic Acid is strictly contraindicated in several patient populations, according to official labeling:

Individuals with known hypersensitivity to the medicine, other NSAIDs, or aspirin.
Patients with active gastrointestinal ulceration, bleeding, or perforation.
Individuals with severe hepatic (liver) impairment or severe renal (kidney) impairment.
Women who are in the third trimester of pregnancy (applies to both oral and topical forms).

Age and Conditional Use

Population Group	Eligibility Status	Rule Basis
Children under 12 years	Not indicated	Oral formulation safety/efficacy not established for this age.
Adults and Adolescents (12+)	Permitted	Authorized indication for use.
Geriatric Population	Use with Caution	Increased risk of adverse effects, requiring monitoring.
Pregnancy (1st & 2nd Trimester)	Not Recommended	Use is subject to warnings and generally avoided unless essential.
Lactating Women	Avoided	Generally not recommended during breastfeeding.

Official documents define eligibility based on these criteria, ensuring use is limited to authorized populations and excluding those with specific comorbidities or life stages that pose a defined risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Niflumic Acid, as a Non-Steroidal Anti-Inflammatory Drug (NSAID), has documented interaction patterns that are classified according to regulatory standards concerning pharmacokinetic and pharmacodynamic outcomes.

Formal Regulatory Restrictions and Outcomes

Co-administration with other NSAIDs, including certain fenamates and Acetylsalicylic Acid at analgesic doses, is formally restricted in regulatory documents. This constraint is based on the significant increase in the risk and severity of adverse effects, particularly gastrointestinal complications.

Pharmacodynamic and Exposure-Altering Interactions

Interacting Agent Category	Officially Documented Interaction Outcome
Anticoagulants/Antiplatelet Agents	Increased risk or severity of bleeding and hemorrhage (additive effect).
Antihypertensive Agents (ACE-I, ARBs, Beta-Blockers)	May decrease the antihypertensive activities of these drugs, reducing efficacy.
Diuretics	Increased risk of deterioration of renal function and reduction of diuretic effect.
Lithium, Digoxin, Renal Excreted Drugs	Niflumic Acid may lower the excretion rate, resulting in raised serum concentrations and increased exposure.

Co-administration with alcohol is also documented to heighten the risk factor for gastrointestinal bleeding. Furthermore, regulatory documents note that in elderly patients or those with pre-existing impaired renal function, the risk of renal function deterioration when combined with Diuretics or ACE-inhibitors is elevated.

Mechanism of Action

The action of Niflumic Acid is based on two principal mechanisms that modulate distinct physiological processes: enzyme inhibition and ion channel blockade. The overall effect is the modulation of physiological processes involving inflammation and nociception.

Inhibition of Prostaglandin Synthesis

The primary mechanism involves the targeted inhibition of Cyclooxygenase enzymes ( COX), particularly COX-2. By blocking the COX enzyme's ability to convert arachidonic acid into prostaglandins (such as PGE2), the drug reduces the key molecular steps that generate inflammatory mediators and alter central thermoregulation. This reduction in PGE2 production directly alters the hypothalamic mechanism that regulates core body temperature and decreases the sensitization of peripheral nociceptive neurons.

Modulation via Chloride Channel Blockade

Niflumic Acid also acts through a secondary, non- COX mechanism: the blockade of specific ion channels, notably Calcium-Activated Chloride Channels ( CaCCs). This molecular interaction alters the flow of chloride ions across cell membranes, which is essential for regulating the electrical stability and responsiveness (excitability) of cells in smooth muscle and nociceptive signaling pathways. This modulation alters the output of dysregulated neural transmission and alters smooth muscle tone via changes in cellular excitability.

Dosage and Administration Information

How to Use Niflumic Acid: Official Administration Guidelines

Administration of Niflumic Acid is organized to accommodate both systemic and local application, aligning with the drug's availability in multiple dosage forms. The official instructions focus on the route, frequency, timing, and duration of use, rather than individual clinical selection.

Official Usage Patterns

Niflumic Acid is supplied for oral ingestion (capsules or tablets) and topical application (gel or cream) for localized use. The standard adult oral dosing regimen is based on a total daily dose generally ranging from 750 mg to 1500 mg, administered in two to three divided administrations throughout the day. Single oral doses typically fall between 250 mg and 500 mg. The topical gel is also intended for application to the affected area two to three times daily.

Administration Requirements

Feature	Official Instruction or Principle
Timing with Meals	Oral preparations are explicitly directed to be taken with food or milk.
Duration Principle	All administration must adhere to the principle of using the lowest effective dose for the shortest duration necessary to achieve symptomatic control.
Frequency Constraint	Doses must be spaced appropriately to ensure the maximum approved daily dose is not exceeded.
Special Populations	Use in older adults generally requires adherence to the lowest effective dose due to altered physiological factors.

These guidelines collectively define the standardized administrative protocol, emphasizing that the course of treatment should remain brief and the dosage must be adjusted within the official parameters.

Recent Clinical Evidence

Research evidence / Overview of studies for Niflumic Acid

Evidence for Symptom Management in Acute Conditions

Research was studied for Niflumic Acid in research scenarios focusing on short-term symptom changes associated with conditions involving periods of heightened symptoms, such as inflammation linked to upper respiratory tract conditions like tonsillitis or pharyngitis. The evidence is derived from Randomized Controlled Trials (RCTs) and Controlled Clinical Trials. These trials research examined outcomes related to physical discomfort and outcomes monitoring physiological strain or stress, such as fever. Studies documented patterns observed in the studies over very defined time intervals, and research provides insight into short-term changes observed during the acute phase. What remains uncertain is the extent of available data regarding patient status following the resolution of these acute symptoms.

Evidence for Localized Musculoskeletal Injuries

Clinical research was evaluated in settings involving localized issues, such as uncomplicated sprains and tendinitis. Specific Double-blind, Placebo-Controlled, Multicenter Trials have been conducted, often focusing on the topical formulation. These studies research examined outcomes linked to inflammatory or irritative states, such as swelling and functional movement. The findings describe patterns observed in the studies where metrics related to pain and inflammation were monitored over the very short follow-up durations (often less than a week). The results apply only to the populations studied and are specific to localized administration for injuries. Limited information exists for long-term outcomes regarding subsequent phases of recovery.

Evidence for Chronic Joint and Inflammatory Disorders

For conditions characterized by fluctuating or episodic manifestations like osteoarthritis (OA) and rheumatoid arthritis (RA), Niflumic Acid was studied for symptomatic effects using Controlled Clinical Trials (CCTs) and Systematic Reviews. These studies research examined outcomes related to systemic or functional imbalance and outcomes reflecting daily functioning. Evidence is limited regarding the long-term observation of these chronic conditions, as many of the foundational trials are older, and contemporary data data are still emerging.

Key Research Gaps and Uncertainties

The evidence base has specific limitations. The sample sizes were modest in some studies, and follow-up durations were limited. While Niflumic Acid is included in reviews of the NSAID class, comparative evidence is lacking for certain indications. The research does not determine whether an individual will respond similarly to the group patterns observed, and data for certain long-term metrics long-term effects are not fully established.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Niflumic Acid (FAQ)

Q: Is Niflumic Acid safe for elderly people?

Official documents note that older adults are at an increased risk of experiencing serious adverse reactions, such as gastrointestinal bleeding and kidney problems. Due to these documented risks, official guidance emphasizes the principle of using the lowest effective dose for the shortest possible duration.

Q: Can Niflumic Acid make me feel dizzy or sleepy?

Official safety documents list certain effects on the nervous system as potential adverse reactions. These commonly include feeling dizzy (vertigo) and drowsiness (sleepiness). These potential effects are part of the information provided by regulatory authorities.

Q: What are the signs of a serious side effect from Niflumic Acid?

Serious risks noted in official warnings include signs of internal bleeding, such as black or bloody stools, and signs of a severe allergic reaction, such as difficulty breathing or swelling of the face or throat. Changes in the amount you urinate may also be noted as a sign of potential kidney issues.

Q: Does Niflumic Acid interact with blood thinners?

Regulatory documents formally describe a potential increase in the risk of bleeding or hemorrhage when the medicine is co-administered with anticoagulants (which includes medicines commonly called blood thinners) and antiplatelet agents.

Q: Is it safe to take Niflumic Acid with other pain relievers?

Official regulatory information formally restricts co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including aspirin used for pain relief, due to a significantly heightened risk of gastrointestinal adverse effects.

Q: What happens if I take Niflumic Acid with alcohol?

Regulatory information describes that co-administration with alcohol is documented to increase the risk factor for gastrointestinal bleeding.

Q: Is Niflumic Acid okay to take if I have asthma?

The medicine is formally contraindicated in individuals with a known history of hypersensitivity to aspirin or other NSAIDs. This class of drugs is associated with a risk of worsening asthma symptoms.

Q: Can Niflumic Acid be used for tooth pain?

The authorized indication for the medicine is the relief of general pain and inflammation. This means the drug is approved for the symptomatic relief of pain associated with various inflammatory conditions.

Q: Is Niflumic Acid usually prescribed short-term or long-term?

Official administration guidelines emphasize the principle of using the lowest effective dose for the shortest duration necessary to achieve symptomatic control. This principle is applied to treatment for both acute and chronic conditions.

Q: Can Niflumic Acid cause an allergic reaction?

Regulatory documents list hypersensitivity to Niflumic Acid or other NSAIDs as a contraindication. Potential adverse effects can include allergic reactions such as rash, itching, and hives.

Q: What evidence supports the use of Niflumic Acid for ear pain?

Clinical evidence has examined the drug's effectiveness in conditions involving inflammation in the upper respiratory tract, such as tonsillitis or pharyngitis. These are related indications that may be associated with localized pain in the ear area.

Q: Why do official documents mention Niflumic Acid is for joint issues?

Official regulatory indications include conditions characterized by joint inflammation and pain, such as osteoarthritis and rheumatoid arthritis. Research supports the use of both oral and topical formulations for these inflammatory issues.

Q: Is Niflumic Acid available over the counter in some countries?

The regulatory status and availability of the medicine (whether it requires a prescription or is available over-the-counter) is specifically determined and defined by the national drug agency where the product is authorized. This status can vary between countries.

Q: Does Niflumic Acid help with muscle cramps?

Beyond its primary anti-inflammatory action, official information notes that the medicine’s effects involve the modulation of smooth muscle tone. This action is achieved through its influence on specific ion channels in the body.

Q: Does Niflumic Acid interact with common cold medicines?

Official documents warn against combining Niflumic Acid with certain classes of medicines that may be present in cold remedies, specifically other NSAIDs and agents that affect blood pressure or kidney function.

Q: Is Niflumic Acid a derivative of Fentanyl or Morphine?

Niflumic Acid is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and chemically belongs to the fenamate subgroup. It is chemically distinct from, and not a derivative of, opioid analgesics like fentanyl or morphine.

Q: Is Niflumic Acid considered addictive?

As a non-opioid NSAID, the medicine is not classified as a controlled substance and is not associated with the addiction potential observed in other analgesic classes.

Q: Can women use Niflumic Acid during menstruation?

The medicine is authorized for the relief of general pain and inflammation, and some regulatory indications for the NSAID class include conditions that may be associated with the menstrual cycle, such as dysmenorrhoea (menstrual pain).

Q: Can Niflumic Acid be crushed or split?

Regulatory guidance for administration specifies whether the oral preparation (capsules or tablets) must be swallowed whole, or if the product's formulation permits crushing or splitting. This information is determined by the specific product's design and formulation.

Q: Is it possible to develop tolerance to Niflumic Acid?

Regulatory authorities generally recognize that as a Non-Steroidal Anti-Inflammatory Drug (NSAID), the medicine is not associated with the development of pharmacological tolerance, unlike certain other types of pain medication.

Q: Can Niflumic Acid affect fertility?

Regulatory documents for the NSAID drug class generally contain a warning concerning a potential, reversible effect on female fertility that is consistent with the drug class.

Q: What is the primary way Niflumic Acid is eliminated from the body?

Pharmacokinetic sections in official documents describe that the drug is mainly eliminated from the body via the renal (kidney) route. This is consistent with its classification and chemical properties.

Q: What happens if a person misses a dose of Niflumic Acid?

Official patient information leaflets provide non-directive guidance for handling a forgotten dose, which typically advises continuing with the next scheduled administration.

Q: Are there differences in the regulatory indications for Niflumic Acid in Europe versus Australia?

Minor variations in authorized indications are often noted between different regulatory agencies, such as the Therapeutic Goods Administration (TGA) in Australia and the European Medicines Agency (EMA). This is due to differing approval processes and review requirements.

Q: Can Niflumic Acid be used for headaches?

The authorized indication for the medicine is the relief of general pain and inflammation. This use covers symptomatic relief for pain associated with various conditions, including headaches.

Q: What does official guidance say about driving while taking Niflumic Acid?

Official guidance specifically addresses the ability to drive or operate machinery. It notes that potential side effects such as dizziness or drowsiness may affect performance and must be considered.

How should Niflumic Acid be stored and disposed of?

How to Store and Dispose of Niflumic Acid?

Niflumic Acid requires specific conditions to maintain stability and prevent environmental harm or unauthorized access. Storage and disposal must strictly follow official regulatory instructions.

Official Storage Requirements

Requirement	Condition
Temperature	Store below 25 C at controlled room temperature.
Environmental Protection	Protect from light and moisture (hygroscopic).
Container	Keep in the original container and tightly closed.
Safety	Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Niflumic Acid must not be disposed of via wastewater or household waste as it may be harmful to aquatic life. Disposal must be conducted according to local regulations for medicinal waste, often requiring return to a pharmacy or a community drug take-back program.

Niflumic Acid